35076-32-5

Basic information

• Product Name: 3-(dimethylamino)-3'-methoxypropiophenone
• Synonyms: 3-(dimethylamino)-3'-methoxypropiophenone;3-(Dimethylamino)-1-(3-methoxyphenyl)-1-propanone
• CAS NO: 35076-32-5
• Molecular Formula: C₁₂H₁₇NO₂
• Molecular Weight: 207.26888
• EINECS: 252-347-4
• Mol File: 35076-32-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 305.4°Cat760mmHg
• Flash Point: 138.5°C
• Appearance: /
• Density: 1.027g/cm³
• CAS DataBase Reference: 3-(dimethylamino)-3'-methoxypropiophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(dimethylamino)-3'-methoxypropiophenone(35076-32-5)
• EPA Substance Registry System: 3-(dimethylamino)-3'-methoxypropiophenone(35076-32-5)

Safety Data

• Hazardous Substances Data: 35076-32-5(Hazardous Substances Data)

Usage

Description

3-(dimethylamino)-3'-methoxypropiophenone, also known as 3-Dimethylamino-1-(3-methoxyphenyl)propan-1-one, is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals. It is characterized by its unique chemical structure, which includes a dimethylamino group and a methoxy group attached to a propiophenone backbone. This structure endows the compound with specific properties that make it valuable in the development of certain medications.

Uses

Used in Pharmaceutical Industry:
3-(dimethylamino)-3'-methoxypropiophenone is used as an intermediate in the synthesis of Oxyfedrine (O870700) for its vasodilatory properties. As a vasodilator, Oxyfedrine affects the coronary base flow, which can be beneficial in treating conditions related to restricted blood flow in the coronary arteries, such as angina pectoris and other cardiovascular diseases.
3-(dimethylamino)-3'-methoxypropiophenone's role in the pharmaceutical industry is primarily as a building block for creating more complex and therapeutically relevant molecules. Its unique structure allows for further chemical modifications and functionalization, which can lead to the development of new drugs with improved efficacy and safety profiles.

Upstream product

• 506-59-2 N,N-dimethylammonium chloride 
• 586-37-8 1-(3-Methoxyphenyl)ethanone 
• 50-00-0 formaldehyd 
• 30354-18-8 N,N-dimethyl(methylene)ammonium chloride 

Downstream Products

• 167642-43-5 1-(3'-methoxyphenyl)-4-nitro-1-butanone 
• 762229-69-6 3-[3-(3-methoxyphenyl)-3-oxopropyl]-1-methyl-piperidin-4-one 
• 108038-15-9 3-(dimethylamino)-1-(3-methoxylbenzene)-1-propanol 
• 253685-11-9 4-[(dimethylamino)methyl]-3-(3-methoxyphenyl)cyclohex-2-enone 
• 1174221-52-3 rac-cis-[4-dimethylaminomethyl-3-hydroxy-3-(3-methoxy-phenyl)-cyclohexanone] 
• 1186119-21-0 2-dimethylaminomethyl-1-(3-methoxyphenyl)hexane-1,5-dione 
• 51594-60-6 1-(3-methoxyphenyl)prop-2-en-1-one 
• 1236376-38-7 3-(2-dimethylaminoethyl)-3-(3-methoxyphenyl)-6,7-dimethyl-isochroman-1-one 

Relevant articles and documents

SMALL MOLECULE CMKLR1 ANTAGONISTS IN INFLAMMATORY DISEASE

α-NETA analogs are provided for the treatment of inflammatory disease.

Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units

Analogues of bedaquiline where the phenyl B-unit was replaced with monocyclic heterocycles of widely differing lipophilicity (thiophenes, furans, pyridines) were synthesised and evaluated. While there was an expected broad positive correlation between lipophilicity and anti-TB activity, the 4-pyridyl derivatives appeared to have an additional contribution to antibacterial potency. The majority of the compounds were (desirably) more polar and had higher rates of clearance than bedaquiline, and showed acceptable oral bioavailability, but there was only limited (and unpredictable) improvement in their hERG liability.

GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS

The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.